AGIX KraneShares Artificial Intelligence ETF

AtheroGenics Inc (NASDAQ: AGIX) announces the following Webcast: What: AtheroGenics Inc Second Quarter 2006 Earnings Conference Call Webcast When: July 20, 2006 @ 09:00 AM Eastern Where: http://www.investorcalendar.com/EventPage.asp?ID=106066 How: Live over the Internet -- Simply log on to the web at the address above. Contact: Donna Glasky, (678)336-2517 or dglasky@atherogenics.com If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=106066 or http://www.investorcalendar.com/ AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III ARISE clinical trial as an oral therapy for the treatment of atherosclerosis, in collaboration with AstraZeneca. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant(R) technology. For more information about AtheroGenics, please visit www.atherogenics.com.